Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07471932
PHASE1

A Study of LAD106 in Healthy Adult Participants

Sponsor: Almirall, S.A.

View on ClinicalTrials.gov

Summary

The main aim of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of single ascending doses of LAD106 (Part A) and multiple ascending doses of LAD106 (Part B) in human healthy participants.

Official title: A Phase 1, Randomized, Two-part, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity and Pharmacodynamics of LAD106 in Healthy Adult Participants

Key Details

Gender

All

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

93

Start Date

2026-02-17

Completion Date

2026-06-30

Last Updated

2026-03-13

Healthy Volunteers

Yes

Interventions

DRUG

LAD106

LAD106 will be administered.

DRUG

Lebrikizumab

Lebrikizumab will be administered.

OTHER

Placebo

Placebo matching LAD106 will be administered.

Locations (1)

Centre for Human Drug Research (CHDR) Phase 1 Unit

Leiden, Netherlands